Xavier Sanchez Flores
Pediatric Dermatology · Dorado, PRNPI 1083032551
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by AbbVie at 50.0% of the total. Reporting peaked in 2024 at $15,229 and has fallen 85.4% since, to $2,224 in 2025.
Across 237 payments — averaging $141.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$17K
- Pierre Fabre Pharmaceuticals, Inc.$8K
- Sanofi$6K
- Johnson & Johnson$981
- E.r. Squibb & Sons, L.L.C.$542
- Eli Lilly Export S.A. Puerto Rico Branch$472
- plus $1K from 14 others
Across 1 payment — averaging $23,668 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly Export S.A. Puerto Rico Branch$24K
What the payments were for
- Consulting fees$12,67538%
- Speaking & faculty fees$5,05315%
- Travel & lodging$7,40522%
- Food & beverage$7,98224%
- Education$4591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 109 | $16,772 |
| Pierre Fabre Pharmaceuticals, Inc. | 5 | $7,586 |
| Sanofi | 28 | $5,859 |
| Johnson & Johnson(2 entities) | 26 | $981 |
| E.r. Squibb & Sons, L.L.C. | 13 | $542 |
| Eli Lilly Export S.A. Puerto Rico Branch | 19 | $472 |
| PBG Puerto Rico LLC | 18 | $385 |
| Pfizer | 3 | $157 |
| Genentech USA, Inc. | 3 | $156 |
| Incyte Corporation | 1 | $135 |
| Lilly USA, LLC | 2 | $100 |
| Merck | 1 | $97 |
| Novartis | 1 | $90 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| GSK | 1 | $51 |
| Amgen | 2 | $36 |
| Revance Therapeutics, Inc. | 1 | $29 |
| Pfizer Pharmaceuticals LLC | 1 | $20 |
| Chiesi USA, Inc. | 1 | $20 |
| Galderma Laboratories, L.p. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few pediatric dermatology providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Taltz AutoinjectorIxekizumab | 26 | $176,272 |
| Dupixent PenDupilumab | 15 | $56,777 |
| Ketoconazole | 46 | $945 |
| Mometasone Furoate | 28 | $733 |
| Clobetasol Propionate | 11 | $683 |
| Triamcinolone Acetonide | 18 | $422 |
| Hydrocortisone | 33 | $380 |
Paid to pharmacies, not to this prescriber.
Other pediatric dermatology in Dorado
- Francisco Colon FontanezSan Juan$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.